» Articles » PMID: 30894502

Intrinsic Cell-penetrating Activity Propels Omomyc from Proof of Concept to Viable Anti-MYC Therapy

Abstract

Inhibiting MYC has long been considered unfeasible, although its key role in human cancers makes it a desirable target for therapeutic intervention. One reason for its perceived undruggability was the fear of catastrophic side effects in normal tissues. However, we previously designed a dominant-negative form of MYC called Omomyc and used its conditional transgenic expression to inhibit MYC function both in vitro and in vivo. MYC inhibition by Omomyc exerted a potent therapeutic impact in various mouse models of cancer, causing only mild, well-tolerated, and reversible side effects. Nevertheless, Omomyc has been so far considered only a proof of principle. In contrast with that preconceived notion, here, we show that the purified Omomyc mini-protein itself spontaneously penetrates into cancer cells and effectively interferes with MYC transcriptional activity therein. Efficacy of the Omomyc mini-protein in various experimental models of non-small cell lung cancer harboring different oncogenic mutation profiles establishes its therapeutic potential after both direct tissue delivery and systemic administration, providing evidence that the Omomyc mini-protein is an effective MYC inhibitor worthy of clinical development.

Citing Articles

MYC in cancer: from undruggable target to clinical trials.

Whitfield J, Soucek L Nat Rev Drug Discov. 2025; .

PMID: 39972241 DOI: 10.1038/s41573-025-01143-2.


Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer.

Xu H, Ma Y, Li H, Song X, Liu Y, Mierzhakenmu Z Breast Cancer (Dove Med Press). 2024; 16:855-866.

PMID: 39655230 PMC: 11626956. DOI: 10.2147/BCTT.S487070.


Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYC.

Ellenbroek B, Kahler J, Arella D, Lin C, Jespers W, Zuger E Angew Chem Int Ed Engl. 2024; 64(4):e202416082.

PMID: 39315681 PMC: 11753601. DOI: 10.1002/anie.202416082.


MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.


Defining neuroblastoma: From origin to precision medicine.

Sainero-Alcolado L, Sjoberg Bexelius T, Santopolo G, Yuan Y, Liano-Pons J, Arsenian-Henriksson M Neuro Oncol. 2024; 26(12):2174-2192.

PMID: 39101440 PMC: 11630532. DOI: 10.1093/neuonc/noae152.


References
1.
Qing G, Li B, Vu A, Skuli N, Walton Z, Liu X . ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012; 22(5):631-44. PMC: 3510660. DOI: 10.1016/j.ccr.2012.09.021. View

2.
Richardson G, Johnson B . The biology of lung cancer. Semin Oncol. 1993; 20(2):105-27. View

3.
Montagne M, Beaudoin N, Fortin D, Lavoie C, Klinck R, Lavigne P . The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLoS One. 2012; 7(2):e32172. PMC: 3284561. DOI: 10.1371/journal.pone.0032172. View

4.
Kalkat M, De Melo J, Hickman K, Lourenco C, Redel C, Resetca D . MYC Deregulation in Primary Human Cancers. Genes (Basel). 2017; 8(6). PMC: 5485515. DOI: 10.3390/genes8060151. View

5.
Fiorentino F, Tokgun E, Sole-Sanchez S, Giampaolo S, Tokgun O, Jauset T . Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016; 7(21):31014-28. PMC: 5058735. DOI: 10.18632/oncotarget.8826. View